Bottom line
As of 2026, approximately 43 percent of large employers (5,000-plus employees) cover GLP-1 medications for weight loss, up from 28 percent in 2024. Getting coverage requires checking your specific plan formulary, obtaining prior authorization with thorough documentation, and being prepared to appeal if initially denied. Well-documented appeals succeed 30 to 50 percent of the time. Your employer's benefits team and your prescriber's office are your two most important allies in this process.
How employer health plans decide on GLP-1 coverage
Employer health plans do not all work the same way, and understanding your plan's structure is the first step toward getting coverage for a GLP-1 medication.
Self-insured vs. fully insured plans
This distinction matters more than almost any other factor in determining your GLP-1 coverage:
Self-insured (self-funded) plans are used by the majority of large employers. In a self-insured plan, your employer pays claims directly rather than purchasing insurance from a carrier. The employer decides what the plan covers, often with guidance from a third-party administrator (TPA) and pharmacy benefit manager (PBM). This means your employer — not an insurance company — makes the ultimate decision about whether to cover GLP-1s for weight loss.
Fully insured plans are more common among smaller employers. The employer purchases a policy from an insurance carrier (UnitedHealthcare, Anthem, Cigna, Aetna, etc.), and the carrier determines covered benefits based on the purchased plan tier. Coverage decisions are made by the insurer, not the employer.
Why this matters: If your employer is self-insured and does not currently cover GLP-1s, there is a real path to changing that through HR advocacy. If your plan is fully insured, changing coverage requires your employer to select a different plan option at renewal.
How plans manage GLP-1 costs
Employers that do cover GLP-1 medications typically use several cost-management strategies:
| Strategy | What it means for you | |---|---| | Prior authorization | You must get approval before filling the prescription | | Step therapy | You must try other treatments first (e.g., lifestyle program, metformin) | | Quantity limits | Typically limited to one pen or one month's supply at a time | | Specialty pharmacy requirement | Must fill through a designated specialty pharmacy | | Mandatory lifestyle program | Must participate in a diet or exercise program alongside medication | | BMI threshold | Must meet a minimum BMI (typically 30, or 27 with comorbidities) | | Duration limits | Coverage may be limited to 12 or 24 months |
Nearly every employer plan that covers GLP-1s requires prior authorization. This is standard, not a red flag.
Step 1: Check your formulary
Before scheduling a prescriber visit, find out whether your plan covers GLP-1 medications at all — and if so, which ones.
How to find your formulary
1. Check your insurer's website. Log into your plan's member portal and search for the formulary or drug list. Search for semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, or Foundayo.
2. Call the member services number on the back of your insurance card. Ask: "Does my plan cover [medication name] for weight management? What tier is it on? Is prior authorization required?"
3. Ask your HR or benefits team. They can often provide a summary of pharmacy benefits, including any GLP-1-specific policies.
Understanding formulary tiers
| Tier | Typical copay | Common GLP-1 placement | |---|---|---| | Tier 1 (generic) | $10–$15 | Not applicable for GLP-1s (no generics in U.S.) | | Tier 2 (preferred brand) | $25–$50 | Rarely — some plans place one GLP-1 here | | Tier 3 (non-preferred brand) | $50–$100 | Occasionally for covered GLP-1s | | Tier 4 (specialty) | 25–40% coinsurance | Most common placement for GLP-1s | | Not covered / excluded | N/A | Many plans exclude GLP-1s for weight loss entirely |
If your plan covers GLP-1s on a specialty tier with coinsurance, your out-of-pocket cost before manufacturer savings cards could be $250 to $500 per month. A manufacturer savings card can reduce this to as little as $25 per month for commercially insured patients.
Step 2: Build your prior authorization package
Prior authorization is a request your prescriber submits to your insurer demonstrating that you meet clinical criteria for the medication. A strong initial submission significantly increases your chances of approval.
Documentation your prescriber should include
- BMI documentation: Measured at the prescriber's office. For weight-loss indication, you need BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- Comorbidity documentation: Lab results, diagnostic codes, and clinical notes supporting any weight-related health conditions.
- Prior weight-loss attempts: Documentation of previous efforts including diet programs, exercise regimens, behavioral counseling, or other medications tried. Many plans require evidence of a failed lifestyle intervention (typically 3 to 6 months).
- Clinical rationale: A letter from your prescriber explaining why this specific medication is medically necessary for your condition. This should reference FDA labeling, clinical guidelines from the American Association of Clinical Endocrinology or the Obesity Society, and your specific clinical history.
Tips for a strong submission
- Include all requested documentation the first time — incomplete applications are the most common cause of delays
- Use the correct diagnosis codes (E66.01 for morbid obesity due to excess calories, E66.09 for other obesity, E11.x for type 2 diabetes)
- Reference the FDA-approved indication specifically
- Have your prescriber's office submit electronically when possible — electronic prior authorization can be approved in 24 to 72 hours versus 5 to 10 business days for paper submissions
Step 3: Navigate a denial
If your prior authorization is denied, do not assume the answer is final. Denials are common, and the appeal process exists for a reason.
Understanding the denial reason
Request the written denial letter. It must include the specific reason for denial, which is usually one of the following:
| Denial reason | What it means | How to address it | |---|---|---| | Medical necessity not demonstrated | Insurer does not believe documentation supports the need | Strengthen documentation of BMI, comorbidities, and failed alternatives | | Step therapy not completed | You have not tried required first-line treatments | Complete the required step or provide evidence why it is inappropriate | | Excluded benefit | Plan does not cover GLP-1s for weight loss | Appeal on medical necessity grounds or pursue HR advocacy | | Incorrect diagnosis code | Administrative error in submission | Correct the code and resubmit | | Preferred alternative available | Plan wants you to try a different GLP-1 first | Switch to the preferred medication or provide clinical justification for the specific one requested |
Filing an internal appeal
Your plan must offer at least one level of internal appeal. The most effective appeals:
1. Cite the plan's exact denial language and address each stated reason directly 2. Include an updated letter of medical necessity from your prescriber that specifically addresses the denial reason 3. Reference clinical guidelines from the American Association of Clinical Endocrinology, the Obesity Society, or the American Heart Association 4. Provide new evidence such as additional lab results, updated BMI measurements, or documentation of worsening comorbidities 5. Request a peer-to-peer review — this is a clinician-to-clinician conversation between your prescriber and the insurer's medical reviewer that can resolve clinical disagreements
External review
If your internal appeal is denied, you have the right to an external review by an independent third party under the Affordable Care Act. This applies to most employer plans. The external reviewer's decision is binding on the insurer.
Step 4: Advocate through your employer
If your plan does not cover GLP-1s at all, or if coverage is inadequate, your employer's HR and benefits team can be powerful allies — especially in self-insured plans.
How to approach HR
1. Frame it as a health and productivity issue. Employers respond to data showing that untreated obesity increases healthcare costs through downstream conditions like diabetes, cardiovascular disease, and joint problems. The long-term cost of covering GLP-1s may be lower than the cost of treating the conditions they prevent.
2. Note the competitive landscape. As of 2026, 43 percent of large employers cover GLP-1s for weight loss. Employers that do not offer coverage risk losing talent to those that do, particularly for roles where benefits packages are a key differentiator.
3. Suggest cost-management guardrails. Rather than asking for open-ended coverage, propose that the employer add GLP-1 coverage with prior authorization, mandatory lifestyle programming, and clinical monitoring. This addresses the employer's cost concerns while still providing access.
4. Connect with colleagues. If multiple employees express interest in GLP-1 coverage, the message carries more weight. Employee benefits surveys are an opportunity to formally request this coverage.
What employers are weighing
Understanding the employer's perspective helps you frame your request effectively:
- Cost impact: GLP-1 medications are estimated to account for 14 percent of all prescription drug spending in 2026. For a self-insured employer, even a small number of employees on GLP-1s can meaningfully affect total claims.
- Utilization concerns: 59 percent of large employers that cover GLP-1s report usage higher than expected, and 66 percent describe the cost impact as significant.
- Stop-loss implications: For self-insured plans, stop-loss carriers are adjusting attachment points and adding specific contract language around GLP-1 claims, which affects the employer's catastrophic cost protection.
- Clinical outcomes: Employers that pair GLP-1 coverage with lifestyle programs report better outcomes and higher treatment completion rates. This pairing approach is becoming the standard model for responsible coverage.
Employer coverage trends in 2026
The landscape is shifting rapidly. Key data points as of mid-2026:
| Metric | 2024 | 2026 | |---|---|---| | Large employers (5,000+) covering GLP-1s for weight loss | 28% | 43% | | Employers reporting higher-than-expected GLP-1 utilization | N/A | 59% | | Employers rating GLP-1 cost impact as significant | N/A | 66% | | GLP-1 share of total prescription drug spending | ~8% | ~14% |
Employers that are not currently covering GLP-1s are generally taking a wait-and-see approach, monitoring pricing trends and waiting for increased market competition to bring costs down. The approval of oral GLP-1 formulations (Wegovy oral tablet, Foundayo) at lower price points is expected to accelerate employer adoption through 2026 and 2027.
Cost to employers: what the numbers look like
For a self-insured employer considering GLP-1 coverage, the math typically looks like this:
- Per-member cost: $12,000 to $16,000 per year per patient on injectable GLP-1s at current net pricing, or $1,800 to $4,200 per year for oral formulations with manufacturer self-pay pricing
- Utilization estimate: 2 to 5 percent of eligible employees will use the benefit in the first year
- Per-employee-per-month (PEPM) impact: Roughly $15 to $40 PEPM for a typical employee population, depending on uptake
- Offset potential: Reductions in downstream costs for diabetes treatment, cardiovascular events, and orthopedic procedures may partially offset GLP-1 spending over 3 to 5 years, though the magnitude and timing of offsets remain debated
Employers with transparent PBM contracts capture the full economic benefit of utilization management. Those with traditional rebate-retention PBM contracts capture less savings because rebate dynamics on GLP-1s can partially offset the benefit of reduced utilization.
Quick reference: your GLP-1 coverage action plan
| Step | Action | Timeline | |---|---|---| | 1 | Check formulary and call member services | Before prescriber visit | | 2 | Visit prescriber with documented weight history and comorbidities | Week 1 | | 3 | Prescriber submits prior authorization with complete documentation | Week 1–2 | | 4 | If approved, fill prescription using manufacturer savings card | Week 2–3 | | 5 | If denied, request denial letter and file internal appeal | Within 30 days of denial | | 6 | If appeal denied, request external review | Within 60 days of appeal denial | | 7 | If plan excludes GLP-1s entirely, begin HR advocacy | Ongoing |
Consult your healthcare provider about whether a GLP-1 medication is appropriate for your health situation. This guide covers the insurance and administrative process, not the clinical decision of whether to take these medications.
[guide:glp1-pharmacy-price-comparison] · [guide:medicare-part-d-glp1-coverage] · [guide:fsa-hsa-for-glp1-medications] · [program:employer-coverage]